Abstract
AbstractRational design and synthetic feasibility are critical factors for the photoaffinity labelling (PAL) approach, which can identify protein targets of bioactive small molecules under native cellular conditions. In this study, we developed photoaffinity labelling probes derived from 1,3,4‐oxadiazin‐5(6H)‐ones (OPALs) for LL‐2003, a previously reported potential anticancer agent against IGF‐1R and Src. Our photoaffinity labelling strategy enabled successful photo‐crosslinking of the probes (OPAL‐6 and OPAL‐8) with the target proteins in both mammalian cell lysates and live MCF7, A549, HepG2 and HeLa cells in situ. In vitro and in situ labelling demonstrated different patterns and expression levels of the proteome, and the strongest band for Src appeared in the A549 cell line. An in‐gel fluorescence scan combined with MS/MS analysis of the IGF‐1R overexpressed insect proteome labelled by OPAL‐6 and OPAL‐8 identified the binding location of the synthesized probes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
